Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Bluebird, Arrowhead And Short Memories

Executive Summary

Last year's platform failure and back to the drawing board status of bluebird bio was all forgotten last week as data on a few patients treated with its CAR-T therapy were released. It seems that investors are quick to forget similar failed or problematic products at Arrowhead, uniQure and Juno.


Related Content

RNA Therapeutics Near A Tipping Point, Says Silence’s CEO
Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal
Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial
Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade
Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration
Stockwatch: A Christmas Medical Conference
Stockwatch: UniQure's guile and the dubious promise of gene therapy
Arrowhead gets $35m bargain for Novartis RNAi assets with Alnylam targets
Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm
Pfizer pulls PAH drug Thelin from market after unpredictable deaths


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts